Harpoon Therapeutics, Inc. (HARP) financial statements (2021 and earlier)

Company profile

Business Address 131 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:15015589
Cash and cash equivalents218989
Short-term investments10559 
Other undisclosed cash, cash equivalents, and short-term investments247 
Deferred costs1  
Other undisclosed current assets(21)(4)1
Total current assets:13015190
Noncurrent Assets
Operating lease, right-of-use asset77
Property, plant and equipment10113
Long-term investments and receivables247 
Long-term investments247 
Other noncurrent assets114
Other undisclosed noncurrent assets  6
Total noncurrent assets:422612
TOTAL ASSETS:172177103
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15108
Accounts payable234
Accrued liabilities1473
Deferred revenue3111
Debt 1 
Contract with customer, liability4
Other undisclosed current liabilities1  
Total current liabilities:482312
Noncurrent Liabilities
Long-term debt and lease obligation1214 
Operating lease, liability1214
Liabilities, other than long-term debt584615
Deferred revenue5846
Contract with customer, liability8
Other liabilities  7
Total noncurrent liabilities:706015
Total liabilities:1188226
Temporary equity, carrying amount  130
Stockholders' equity
Stockholders' equity attributable to parent5494(53)
Common stock000
Additional paid in capital2222129
Accumulated other comprehensive income00 
Accumulated deficit(168)(118)(63)
Total stockholders' equity:5494(53)
TOTAL LIABILITIES AND EQUITY:172177103

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:1765
Operating expenses(69)(64)(32)
Operating loss:(51)(58)(28)
Nonoperating income130
Investment income, nonoperating130
Loss before gain (loss) on sale of properties:(50)(55)(27)
Other undisclosed net loss (1) 
Net loss available to common stockholders, diluted:(50)(56)(27)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(50)(56)(27)
Other comprehensive income (loss)(0)0 
Comprehensive loss, net of tax, attributable to parent:(50)(56)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: